Secret NIH Huddle: Alzheimer's Grants Get Private Review in Virtual Shadows
Published Date: 3/20/2025
Notice
Summary
The National Institute on Aging is holding a closed virtual meeting on April 11, 2025, to review grant applications focused on managing early and late Alzheimer's disease. This meeting affects researchers seeking funding and keeps sensitive info private. No money changes now, but decisions could impact future Alzheimer's research funding.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 0 costs, 1 mixed.
NIH grant review for Alzheimer’s clinical trials
If you are a researcher seeking NIH funding for clinical trials on early- or late-stage Alzheimer’s disease, your grant applications will be reviewed at a closed virtual meeting on April 11, 2025, from 10:00 a.m. to 6:00 p.m. The meeting will evaluate and decide on grant applications, and those decisions could affect future Alzheimer's research funding.
Confidential review to protect trade secrets and privacy
The meeting will be closed to the public under 5 U.S.C. 552b(c)(4) and (c)(6) to protect confidential trade secrets, patentable material, and personal information of applicants. If you apply for these grants, the review process will keep commercially sensitive information and personal data private.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-17438, Center For Scientific Review; Notice of Closed Meetings
The NIH's Center for Scientific Review is holding several closed virtual meetings in late September 2026 to review and evaluate grant applications. These meetings protect private info and trade secrets, affecting researchers applying for funding. No direct money changes are announced, but these reviews decide who gets research grants.
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
Previous / Next Documents
Previous: 2025-04733, National Institute on Aging; Notice of Closed Meeting
The National Institute on Aging is holding a private virtual meeting on April 9, 2025, to review grant applications for aging-related clinical trials. This meeting affects researchers seeking funding and keeps sensitive info safe. No public access or money changes are involved, but it’s a key step in deciding who gets research support.
Next: 2025-04735, Indian Gaming; Approval by Operation of Law Tribal-State Class III Gaming Compact Amendment Between the Chitimacha Tribe of Louisiana and the State of Louisiana
The Chitimacha Tribe of Louisiana and the State of Louisiana just got a green light to extend their gaming agreement for 7 more years! This update also raises the money limits for licensing and certifying vendors who work with the Tribe’s casinos. It means smoother operations and more time for everyone to enjoy the gaming fun.